Navigation Links
World class technology and talent battle cancer at the Centenary Institute
Date:11/26/2007

The Centenary Institute, one of Australias leading medical research institutes, unveiled a powerful microscope unlike any other in Australia today. Representing the cutting edge in medical technology and microscopy, the unique imaging features of the multiphoton microscope will enable scientists at the Centenary Institute unprecedented access to the secret workings of living tissues at the cellular and molecular level.

The Centenary Institute is equally excited about the arrival of Austrian Professor Wolfgang Weninger, one of only a handful of people in the world who specialises in using the multiphoton microscope in the immunology field to view immune responses in real-time in living tissue.

At the Centenary, Professor Weninger will lead a team of researchers to study the dynamics of the immune systems response to cancer and infectious diseases.

Professor Weninger said, Cancer is still a leading cause of death in Australia. There is a need to develop improved anti-cancer therapies based on the use of the bodys own resources - namely our immune system. This type of microscope is an outstanding tool to study how our bodies fight cancer both in early and advanced stages. If we can learn more about how our immune system attacks cancer cells directly in the context of intact tissues, we hope to develop improved immuno-therapies.

Using the multiphoton microscope, Professor Weningers team pioneered ground-breaking imaging models to record how the bodys defences fight tumours and infectious diseases. He has already astounded the medical community in Australia and the world by showing real-time videos of white blood cells invading and destroying cancer cells in living tissue. Centenarys Executive Director, Professor Mathew Vadas said, The arrival of Professor Weninger and the multiphoton microscope marks a new era in medical research for the Centenary Institute.

With one of his recently published papers among the ten all-time highest-ranked papers in biomedicine, we are honoured to have such an eminent researcher as Professor Weninger join the Centenary Institute.

I am confident that the results of his teams research will vastly improve our understanding of how the bodys immune system fights cancer and infectious diseases. The multiphoton microscope will also support the research of other Centenary scientists particularly in autoimmune and liver diseases.

The multiphoton microscope at the Centenary Institute has two unique features, its imaging mode and laser. The unique imaging mode uses multiple laser beams and means fast moving objects and dynamic processes in living tissue can be viewed, for example, cells in the blood stream. The laser has been enhanced with a unit called an OPO that produces longer wavelengths of light than those used in other microscopes enabling researchers to potentially look deeper into living tissue than ever before.


'/>"/>

Contact: Jane Moloney
j.moloney@centenary.org.au
61-295-656-118
Research Australia
Source:Eurekalert

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
3. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Childrens Fitness
6. Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention
7. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
8. Depression May Be Worlds Most Disabling Disease
9. Concentra Opens On-Site Medical Unit at World Trade Center Site
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. Womens World Banking Welcomes New Network Member From Tunisia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: